 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk
of gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT 
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk
of gastrointestinal ulcer hospitalization?
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "drug": "haloperidol"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: HALOPERIDOL: adverse_reactions: There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that
all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, 
this syndrome may be masked. It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time, the full 
syndrome may not develop. Tardive Dystonia Tardive dystonia, not associated with the above syndrome, has also been reported. Tardive dystonia is characterized by delayed onset of choreic or dystonic 
movements, is often persistent, and has the potential of becoming irreversible. HALOPERIDOL: adverse_reactions: Other CNS Effects Insomnia, restlessness, anxiety, euphoria, agitation, drowsiness, 
depression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations and catatonic-like behavioral states which may be responsive to drug
withdrawal and/or treatment with anticholinergic drugs. Body as a Whole: Neuroleptic malignant syndrome (NMS), hyperpyrexia and heat stroke have been reported with haloperidol. (See WARNINGS for 
further information concerning NMS.) Hematologic Effects: Reports have appeared citing the occurrence of mild and usually transient leukopenia and leukocytosis, minimal decreases in red blood cell 
counts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of haloperidol, and then only in association with other medication. 
HALOPERIDOL: adverse_reactions: Liver Effects: Impaired liver function and/or jaundice have been reported. Dermatologic Reactions: Maculopapular and acneiform skin reactions and isolated cases of 
photosensitivity and loss of hair. Endocrine Disorders: Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and 
hyponatremia. Gastrointestinal Effects: Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting. Autonomic Reactions: Dry mouth, blurred vision, urinary retention, 
diaphoresis and priapism. Respiratory Effects: Laryngospasm, bronchospasm and increased depth of respiration. Special Senses: Cataracts, retinopathy and visual disturbances. HALOPERIDOL: 
adverse_reactions: Post-marketing Events Hyperammonemia has been reported in a 5-1â„2 year old child with citrullinemia, an inherited disorder of ammonia excretion, following treatment with 
haloperidol.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: openfda: spl_set_id         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: geriatric_use: Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from 
younger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia 
appears to be highest among the elderly, especially elderly women (see WARNINGS: Tardive Dyskinesia ). Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of 
lower doses (see DOSAGE AND ADMINISTRATION ).         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: openfda: package_ndc         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: openfda: pharm_class_epc         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: warnings: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular 
pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure. The 
diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness
(e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central 
anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. HALOPERIDOL: warnings: The management of NMS should include 1) immediate discontinuation of 
antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for 
which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after
recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia and
heat stroke, not associated with the above symptom complex, have also been reported with haloperidol. Falls Haloperidol tablets, USP may cause somnolence, postural hypotension, motor and sensory 
instability, which may lead to falls and, consequently, fractures or other injuries. HALOPERIDOL: warnings: For patients with diseases, conditions, or medications that could exacerbate these effects, 
complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Usage in Pregnancy Pregnancy Nonteratogenic Effects Neonates 
exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, 
hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other 
cases neonates have required intensive care unit support and prolonged hospitalization. Haloperidol should be used during pregnancy only if the potential benefit justifies the potential risk to the 
fetus. HALOPERIDOL: warnings: Rodents given 2 to 20 times the usual maximum human dose of haloperidol by oral or parenteral routes showed an increase in incidence of resorption, reduced fertility, 
delayed delivery and pup mortality. No teratogenic effect has been reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given 15 times the usual 
maximum human dose. Cleft palate in mice appears to be a nonspecific response to stress or nutritional imbalance as well as to a variety of drugs, and there is no evidence to relate this phenomenon to
predictable human risk for most of these agents. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following 
maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. 
HALOPERIDOL: warnings: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only 
if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Combined Use of Haloperidol and Lithium An encephalopathic syndrome (characterized 
by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few 
patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients 
receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: precautions: Therefore, although not optimal, this study does suggest the absence of a haloperidol related increase in the incidence of neoplasia in rats at doses up to 20 times 
the usual daily human dose for chronic or resistant patients. In female mice at 5 and 20 times the highest initial daily dose for chronic or resistant patients, there was a statistically significant 
increase in mammary gland neoplasia and total tumor incidence; at 20 times the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no 
statistically significant differences in incidences of total tumors or specific tumor types were noted. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic 
administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these
drugs is contemplated in a patient with a previously detected breast cancer. HALOPERIDOL: precautions: Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been 
reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of 
antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; 
the available evidence is considered too limited to be conclusive at this time. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb 
malformations observed following maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not 
established in these cases. HALOPERIDOL: precautions: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women 
likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Pediatric Use Safety and effectiveness in pediatric 
patients have not been established. Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from 
younger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia 
appears to be highest among the elderly, especially elderly women (see WARNINGS: Tardive Dyskinesia ). Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of 
lower doses (see DOSAGE AND ADMINISTRATION ).         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: general_precautions: General A number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. It has been postulated that 
lethargy and decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, 
especially in the elderly, the physician should institute remedial therapy promptly. Although not reported with haloperidol, decreased serum cholesterol and/or cutaneous and ocular changes have been 
reported in patients receiving chemically-related drugs. Haloperidol may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or 
driving a motor vehicle. The ambulatory patient should be warned accordingly. The use of alcohol with this drug should be avoided due to possible additive effects and hypotension.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: clinical_pharmacology: CLINICAL PHARMACOLOGY The precise mechanism of action has not been clearly established.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: openfda: spl_id         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: openfda: product_ndc         
SOURCE:HALOPERIDOL label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE>
ANSWER: The available information from the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list 
gastrointestinal effects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but it does not directly link HALOPERIDOL to gastrointestinal 
ulcer hospitalization.
SOURCE: HALOPERIDOL label
EXTRACT_START_END: Gastrointestinal Effects: Anorexia, constipation...nausea and vomiting.
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) ANSWER: The available information from the 
HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list gastrointestinal effects such as anorexia, 
constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but it does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization.
SOURCE: HALOPERIDOL label
EXTRACT_START_END: Gastrointestinal Effects: Anorexia, constipation...nausea and vomiting.
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization.",
      "FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal 
effects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer 
hospitalization."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization.",
      "FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal 
effects such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer 
hospitalization."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does HALOPERIDOL increase or decrease the risk of gastrointestinal ulcer hospitalization?
        -----
        Reasoning:
        1. I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of gastrointestinal ulcer hospitalization.
2. FDAHandler responded that the HALOPERIDOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists gastrointestinal effects
such as anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, but does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": ""
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "",
    "request": "feedback"
  }
}
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) Your reasoning is valid, no feedback was 
provided.
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.USER 
 (orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-gastrointestinal ulcer hospitalization-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

The FDA label for HALOPERIDOL does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. While the label lists gastrointestinal effects such as 
anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea, and vomiting as adverse reactions, it does not directly link HALOPERIDOL to gastrointestinal ulcer hospitalization. Therefore, we 
cannot determine from the FDA label whether HALOPERIDOL affects the risk of gastrointestinal ulcer hospitalization.
